Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | No. 4 The Forum, Grenville Street SAINT HELIER JE2 4UF |
Tel: | N/A |
Website: | https://www.novocure.com |
IR: | See website |
Key People | ||
William F. Doyle Executive Chairman of the Board | Asaf Danziger President, Chief Executive Officer, Director | Ashley Cordova Chief Financial Officer |
Wilhelmus C. M. Groenhuysen Chief Operating Officer | William Burke Chief Human Resource Officer | Frank X. Leonard Executive Vice President and President - Novocure Oncology |
Barak Ben-Arye General Counsel | Nicholas Leupin Chief Medical Officer | Uri Weinberg Chief Innovation Officer |
Business Overview |
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer. |
Financial Overview |
For the fiscal year ended 31 December 2023, Novocure Ltd revenues decreased 5% to $509.3M. Net loss increased from $92.5M to $207M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Sales and marketing - Balancing value increase of 32% to $190.8M (expense), General and administrative - Balancing increase of 36% to $122.8M (expense), Research. |
Employees: | 1,453 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,058M as of Dec 31, 2023 |
Annual revenue (TTM): | $509.34M as of Dec 31, 2023 |
EBITDA (TTM): | -$221.89M as of Dec 31, 2023 |
Net annual income (TTM): | -$207.04M as of Dec 31, 2023 |
Free cash flow (TTM): | -$100.43M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 107,093,432 as of Feb 16, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |